Brain puzzle concept
Your Support
Sign Up for Newsletter

Recurrent H3 K27M-mutant Diffuse Midline Glioma or DMG, is a rare, but aggressive type of high-grade glioma found in the midline or central structures of the brain, including the thalamus, brainstem, pons and spinal cord, that controls many important body functions. [1][2] Some of these functions are crucial for survival.  It’s uncommon for DMG to occur in other areas of the central nervous system (CNS).

DMG, defined by a specific genetic alteration known as H3 K27M mutation, this specific genetic mutation disrupts epigenetic regulation and drives tumor growth.[3]

Although the cause of DMG is not known, patients a certain inherited genetic disorders, including Li-Fraumeni Syndrome (LFS) and constitutional mismatch repair deficiency syndrome (CMMRD), have an increased risk of developing DMGs. However, DMG also develops without an underlying genetic predisposition.

The disease is further characterized by its diffuse nature, since the cells infiltrate normal or healthy brain tissue, making it difficult to surgically remove. And while surgical removal is not an option, a biopsy to help physicians determine the diagnosis and identify molecular characteristics of each tumor, is safe.

Your Support
Sign Up for Newsletter

Recurrent H3 K27M-mutant Diffuse Midline Glioma is most commonly diagnosed in children between 6 and 10 years of age. However, the disease is also increasingly recognized in (young) adults. Patients with this type of glioma often face an extremely poor prognosis, with limited therapeutic options and very low survival rates following recurrence.[5]

Advertisement #3

Median survival is approximately one year from diagnosis and less than six months after progressing following frontline therapy.[5]

To date, the most effective, standard treatment for DMG. And while the disease and remains incurable, treatment includes radiation therapy. However, this approach is a ‘short-term,’ not a cure. Other treatment options include chemotherapy and select targeted therapies, some of which are in early and late stage clinical development.

Novel drug approval
The U.S, Food and Drug Administration recent approved dordaviprone (Modeyso™; Jazz Pharmaceuticals), may bring new hope to patients diagnosed with this ultra-rare and aggressive brain tumor.

The FDA’s accelerated approval of dordaviprone for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy was based on an overall response rate in patients with progressive disease following prior therapy.[1]

Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial.[1]

Turning point
Dordaviprone is the first and only treatment option approved by the FDA for this ultra-rare and aggressive brain tumor that affects an estimated 2,000 people in the U.S. each year, many of whom are children and young adults.[2] The disease is characterized by rapid progression and historically has had no effective systemic treatment options. [3] To address this urgent unmet patient need, dordaviprone is expected to be commercially available in the coming weeks.

“This is a major turning point in neuro-oncology,” noted Patrick Wen, M.D., Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute and Professor of Neurology, Harvard Medical School.

“For the first time, we have an FDA-approved therapy for patients with recurrent H3 K27M-mutant diffuse midline glioma. While outcomes remain challenging for many patients, the objective responses observed with dordaviprone, including durable benefit in some patients, represent a meaningful advancement. This therapy was developed with the underlying biology of the tumor in mind and introduces a new treatment option for a population with historically limited choices.”

Dordaviprone is administered as an oral capsule once weekly. The FDA’s decision was based on an integrated efficacy analysis of 50 patients with recurrent H3 K27M-mutant diffuse midline glioma, selected from five open-label clinical studies based on prespecified eligibility criteria.

The overall response rate (ORR), as assessed by blinded independent central review (BICR) using Response Assessment in Neuro-Oncology (RANO) 2.0 criteria, was 22% (95% CI: 12 to 36), with an additional responder identified by integrated RANO 2.0. Among responders, the median duration of response was 10.3 months (95% CI: 7.3 to 15.2), with 73% maintaining their response for at least six months and 27% for at least 12 months.[6]

“The FDA approval of dordaviprone is a milestone moment for the patients and families who have long needed new options, the clinicians who have tirelessly searched for solutions, and the researchers and advocates who never gave up,” explained Joshua E. Allen, Ph.D., Chief Scientific Officer, Chimerix, a Jazz Pharmaceuticals Company.

“We’re proud to deliver precisely the kind of transformative innovation we strive for, and we congratulate our combined Chimerix and Jazz team, and the community who worked together tirelessly to bring this treatment forward. This approval not only equips clinicians with the first targeted option for this disease but also signals a meaningful shift in what patients and families can expect after diagnosis. We would like to extend our thanks to the patients, advocates, clinicians, principal investigators, scientists, regulators and partner institutions who made this possible,” Allen added.

“This approval represents a long-awaited treatment option for families affected by H3 K27M-mutant diffuse midline glioma,” said David F. Arons, President and Chief Executive Officer of the National Brain Tumor Society.

“This is a fast-moving, devastating disease that turns families’ lives upside down. For years, this diagnosis has lacked an approved treatment and today, that changes. Families finally have a treatment option, and a reason to believe in more time together to make memories that might not have otherwise been possible,” Arons concluded.

Study design
The efficacy and safety of dordaviprone were evaluated in adult and pediatric patients with glioma across five open-label, non-randomized clinical studies (ONC006, ONC013, ONC014, ONC016, and ONC018). A pre-specified integrated efficacy analysis included 50 patients with recurrent H3 K27M-mutant diffuse midline glioma who had measurable disease per Response Assessment in Neuro-Oncology (RANO) criteria. Tumor response was assessed every eight weeks by blinded independent central review (BICR). The primary efficacy endpoint was objective response rate (ORR). Safety was evaluated across four of the clinical studies.[7]

Study outcome
The safety of dordaviprone was evaluated in 376 adult and pediatric patients with glioma across four open-label clinical studies. Serious adverse reactions occurred in 33% of patients. Serious adverse reactions reported in more than 2% of patients included hydrocephalus (5%), vomiting (4.3%), headache (3.2%), seizure (2.4%) and muscular weakness (2.1%).

The most common adverse reactions in patients who received dordavipronec(≥20%) were fatigue, headache, vomiting, nausea and musculoskeletal pain.[7]

Clinical trials
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION) – ClinicalTrials.gov ID NCT05580562
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma – ClinicalTrials.gov ID NCT03295396
Oral ONC201 in Adult Recurrent Glioblastoma – ClinicalTrials.gov ID NCT02525692
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/​or Midline Gliomas – ClinicalTrials.gov ID NCT04617002
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer – ClinicalTrials.gov ID NCT03485729
ONC201 in Pediatric H3 K27M Gliomas – ClinicalTrials.gov ID NCT03416530
A Study of ONC201 for Refractory Meningioma – ClinicalTrials.gov ID NCT06012929
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant – ClinicalTrials.gov ID NCT03932643
Testing ONC201 to Prevent Colorectal Cancer – ClinicalTrials.gov ID NCT05630794

Highlights of prescribing information
Dordaviprone (Modeyso™; Jazz Pharmaceuticals) [Prescribing Information]

References
[1] ZS Epidemiology Analysis. Jazz Pharmaceuticals. Data on File. Durham, NC; 2025.
[2] Arrillaga-Romany, I., Lassman, A., et al. A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-oncology. 2024; 26(Supplement_2), S173-S181.
[3] Yang, Z., Sun, L., Chen, et al. New progress in the treatment of diffuse midline glioma with H3K27M alteration. Heliyon. 2024;10(2).
[4] Diffuse Midline Glioma: Diagnosis and Treatment. National Cancer Institute. Updated August 20, 2024. Online. Last accessed on July 23, 2025.
[5] Bagley, S. J., Umemura, et al. Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma. Cancers. 2025; 17(13):2107. DOI: 10.3390/cancers17132107

Featured image: Brain puzzle. Photo courtesy: © 2019  – 2025 Fotolia/Adobe. Used with permission


DOI

Sign Up for Newsletter
Your Support

Advertisement #5